GET THE APP

Controlled Ovarian Hyperstimulation through Gonadotrophin releasing Hormone Agonist for Patients at Risk of Hyperstimulation Syndrome | Abstract
Journal of Fertilization: In Vitro - IVF-Worldwide, Reproductive Medicine, Genetics & Stem Cell Biol

Journal of Fertilization: In Vitro - IVF-Worldwide, Reproductive Medicine, Genetics & Stem Cell Biol
Open Access

ISSN: 2375-4508

+44 20 3868 9735

Abstract

Controlled Ovarian Hyperstimulation through Gonadotrophin releasing Hormone Agonist for Patients at Risk of Hyperstimulation Syndrome

Antonio Maselli, Martin Wilding, Sylvia del Grande, Stefania Riccio, Loredana Di Matteo and Brian Dale

Background:Patients at high risk of OHSS can experience difficulty in completing an IVF cycle with the administration of gonadotrophins. Here, we test a unique low-dose GnRH agonist protocol.

Methods: 0.1mg triptorlin acetate (decapeptyl) was administered to 18 patients at high risk of OHSS from day 5 of the menstrual cycle. Oocyte retrieval was performed 36 hours after the administration of 10000 IU human chorionic gonadotrophin, when follicles of 18-20mm were observed. Oocytes were fertilised in vitro and embryos transferred on day 3.

Results: Patients produced a mean of 4.1 ± 0.96 oocytes. After ICSI, a mean of 3.0 ± 0.84 embryos were transferred to the uterus. A total of 5 pregnancies were obtained from the 18 cycles. No patients were affected by OHSS.

Conclusions: Low-dose injections of GnRH analogues can cause multiple follicular development, mature oocytes and pregnancies in patients at risk of OHSS. This novel COH protocol appears safe and applicable as a valuable alternative to the natural cycle.